Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and Fran...
T. Aurran-Schleinitz, R. Letestu, M. Sartor et al.· British Journal of Haematolo...· 0 citations
The Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) defined GATA2 deficiency as any of the 2,903 combinations of two or three phenotypes with log10Odds Ratio ≥3 (OR ≥ 1000).
S. Mohan, Tilda E Carlelycke, Ashwin L Koppayi et al.· Blood· 0 citations
The spectrum of genetic lesions that result in activation of NF‑κB in mature B‑cell malignancies is expanded and highlights the incomplete understanding of NF‑κB drivers in mature B‑cell malignancies.
E. Li, L. Heitink, E. Bandala-Sanchez et al.· Blood· 0 citations
How CRISPR-enabled functional genomics approaches can reveal unexpected cancer dependencies and resistance mechanisms is outlined, and emerging applications of CRISPR-based diagnostics in oncology that convert precise nucleic acid sequence recognition into rapid mutation detection are discussed.
S. Grigg, Carolyn Shembrey, M. Fareh et al.· Nature Reviews Clinical Onco...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.